Author: admin

  • 50-Year-Old Making $5,900 A Month In Dividends Shares Top 7 Stocks, Plans Exit From 9-to-5 – ‘I’m Sick Of Corporate World’

    50-Year-Old Making $5,900 A Month In Dividends Shares Top 7 Stocks, Plans Exit From 9-to-5 – ‘I’m Sick Of Corporate World’

    Dividend stocks are gaining attention amid growing expectations that the Federal Reserve will cut interest rates by 25 basis points next month. Data from Purpose Investments showed inflows into the five largest dividend ETFs surged tenfold last month compared with the start of 2024.

    In June, an investor shared his dividend income and portfolio details on r/Dividends, a Reddit community of income investors with over 750,000 followers. The poster, 50, said he’s slowly moving from growth to dividend stocks and nearing early retirement.

    In a separate post, the investor said his annual salary is roughly $350,000, but he is “sick” of the corporate world and plans to retire soon.

    Don’t Miss:

    “I’m sick of the corporate world and the 9-5 (I wish it was only 8 hour days!) rat race,” he wrote. “Maybe it’s a mid-life crisis or maybe I’m just finally thinking ‘I have enough’, but I’m hoping to pull the trigger as soon as possible.”

    The portfolio screenshots shared by the investor showed that his dividend income was about $5,900 per month.

    Let’s take a look at some of the top dividend stocks in the investor’s portfolio.

    JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ) is a high-yield covered call ETF that distributes monthly dividend income. The ETF invests in Nasdaq companies and generates extra income by selling call options. The fund has a dividend yield of 11%.

    Trending: An EA Co-Founder Shapes This VC Backed Marketplace—Now You Can Invest in Gaming’s Next Big Platform

    Altria Group (NYSE:MO) has a 7.6% dividend yield and over 50 years of consistent dividend growth history. It’s one of the most popular high-yield dividend stocks among income investors on Reddit.

    The YieldMax MSTR Option Income Strategy ETF (NYSE:MSTY) generates income by selling call options on Strategy (NASDAQ:MSTR) stock. The fund is down about 32% so far this year.

    PIMCO Dynamic Income Fund (NYSE:PDI) is a high-yield fixed-income fund that invests in debt securities, including mortgage-backed securities and bonds from developed and emerging markets. PDI yields about 14% and pays monthly dividends.

    Continue Reading

  • 5 Things That Don’t Mix Well with Your Diabetes Medications

    5 Things That Don’t Mix Well with Your Diabetes Medications

    • Some foods and drinks interfere with the way some diabetes medications work.
    • High fat meals, alcohol and refined carbs can impact the effectiveness of some diabetes medications.
    • When taking diabetes medications, make sure you stay hydrated and consider meal timing and portions.

    When you have diabetes, the focus is often on eating a healthy diet to better manage the disease and timing your meals with your medications. But understanding what specific foods and drinks interact with your medications is also key. “Diabetes medications are designed to work in a very specific way to help control your blood sugar,” says Elaina Rosario, Pharm.D., CPh, BCACP, CDCES. “When you eat certain foods, they can change how your medication is absorbed, how it works in your body, or how quickly it is used up. This can sometimes make the medication less effective, or in some cases, too strong.” 

    Rebecca Emch, Pharm.D., agrees, “From a pharmaceutical perspective, food interactions with diabetes medications occur through several mechanisms.” The effects vary depending on the type of medication you’re taking. “For medications like metformin, certain foods can affect absorption rates and bioavailability,” says Emch. However, this type of interaction isn’t as common since many times the foods in the diet don’t directly affect absorption of the medications. Instead, Emch says that it’s more common that foods eaten work against their intended purpose. “When you take a diabetes medication to lower blood sugar, and then consume foods that cause rapid glucose spikes, you’re essentially creating a tug-of-war in your system,” she says. Other foods like those high in fat may also have an impact. 

    Because of these effects, Cari Riker, RDN, LDN, CDCES emphasizes the importance of following a diet that helps you best manage your blood sugar while also preventing medication interactions. “Selecting foods that reduce these impacts can help improve tolerance and effectiveness,” says Riker. We’re sharing which types of foods may interact with your diabetes medications and tips on how to stay safe.

    1. High Fat Foods

    Some dietary fats like unsaturated fats are beneficial for health, but saturated fats in excess are associated with an increased risk for type 2 diabetes. Additionally, meals that are high in fat may affect the bioavailability of certain medications. “High-fat foods slow digestion which delays how quickly some medications are absorbed and when they take effect,” says Daria Zajac, RD, LDN. “Examples of high fat foods include whole-fat dairy products, processed meats, fried foods and baked goods like cookies and cake.” Not only can they slow down how fast a medication works, according to Rosario, they can also trigger the gastrointestinal side effects of glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as nausea, vomiting and diarrhea.

    2. Foods High in Added Sugar

     “Limiting high-sugar foods can help prevent rapid spikes and crashes in blood sugar,” says Riker. This is because foods with added sugar may make it more difficult for your diabetes medication to work as intended. Emch points to high sugar foods like candy, sodas and desserts as well as fruit juices as some of the biggest culprits when it comes to foods that work against your diabetes medication. 

    “These don’t stop medications like metformin from working, but they make it significantly harder to maintain stable blood sugar levels,” says Emch. “It’s like trying to bail water out of a boat while someone else is pouring more water in.” This doesn’t mean avoiding all foods with carbohydrates and sugar. Instead, focus on whole food sources of carbohydrates that are also natural sources of fiber like beans and legumes, whole grains, and whole fruits and vegetables whenever possible. “The quality and quantity of carbohydrates matter,” says Riker.

    3. Highly Processed and Refined Carbohydrates

    Foods that are primarily carbohydrates and are also highly processed like white bread, high sugar cereals, chips, pretzels, crackers and baked goods like croissants, cookies and pies can often cause a spike in your blood sugar. “If you take a fast-acting insulin or a medication that works with meals, this sudden spike can make it difficult for the medication to keep up, or it could lead to a sudden drop later if the medication works too aggressively to bring it down,” says Rosario.

    “While your diabetes medication is designed to manage blood sugar, it’s much easier for it to work effectively when your blood sugar levels are kept more stable.” If you choose to include highly processed or refined carbohydrates in your diet, it can help to pair them with protein or fat as part of a balanced meal. This combination can help to slow digestion which may prevent blood sugar spikes.

    However, most of the diet should not be made up of highly processed carbohydrate sources. “The American Diabetes Association (ADA) specifically recommends that people with diabetes preferentially eat minimally processed sources of carbohydrate that are high in fiber,” says Joshua J. Neumiller, Pharm.D., CDCES, FADCES, FASCP, president of health care & education at the American Diabetes Association.

    4. Caffeine

    Medications that are in the class of SGLT2 inhibitors like Jardiance, Steglatro, and Farxiga work by allowing excess sugar to be removed via urine. The diuretic effect of these medications may be compounded by the diuretic effect of excess caffeine. This doesn’t mean a cup of coffee or two will be a cause for concern, but those taking these medications should consider sticking to the recommended limit of 400mg caffeine per day (or approximately three to four cups of coffee).

    5. Alcohol

    “Alcohol should be limited when taking diabetes medications,” says Zajac. Drinking alcohol on an empty stomach or when skipping meals may worsen the effect it has when taking diabetes medications. “Alcohol increases the risk of low blood sugar, especially for those taking insulin or sulfonylureas, since it interferes with the liver’s ability to release glucose into the bloodstream,” says Riker. 

    Riker also says that alcohol can worsen side effects like nausea and digestive upset when taking medications like metformin. “For those on SGLT2 inhibitors (i.e. Jardiance, Farxiga), alcohol’s dehydrating effects can increase the chances of dehydration, low blood pressure and rare but serious complications like diabetic ketoacidosis (DKA).”

    Following recommendations to limit alcohol is essential when undergoing diabetes treatment. “The ADA recommends that people with diabetes consume alcohol in moderation by limiting intake to ≤2 drinks per day for men and ≤1 drink per day for women,” says Neumiller. “It is important that people with diabetes understand that hypoglycemia can be delayed after drinking alcohol and that blood glucose levels should be monitored carefully to prevent severe low blood glucose levels.” For these reasons, it’s recommended that any alcohol intake is discussed with your doctor pharmacist.

    How to Stay Safe

    With so many diabetes medications available today, it’s difficult to provide one-size-fits-all recommendations when it comes to your diet and food choices. “Your pharmacist is a great resource for understanding how best to take your diabetes medications in relation to meals and if any specific types of foods should be avoided with your prescribed medications,” says Neumiller. These tips can get you started with making changes that work best for you.

    Consider Meal Timing: Be sure to time meals and snacks appropriately depending on what’s recommended for your medication as different medications can have different effects. “Some medications need to be taken with the first bite of a meal, while others are taken 30 minutes before, and some are taken with your evening meal,” says Rosario. “Missing the right timing can affect how well the medication works.”

    Stay Hydrated: “Hydration is essential, especially for those on SGLT2 inhibitors like Jardiance or Farxiga, which can increase fluid loss and raise the risk of dehydration or electrolyte imbalance,” says Riker. Drink primarily water and other unsweetened beverages to promote optimal hydration.

    Consider Portion Sizes: Some medications may require paying special attention to portion sizes than others. “For those on GLP-1 receptor agonists such as Ozempic, Trulicity, or Victoza, large or high-sugar meals may worsen nausea or lead to dumping syndrome,” says Riker.

    Monitor Your Numbers: “A tool that can be used to monitor how foods affect your blood sugar is a continuous glucose monitor,” says Rosario. “They are available with a prescription and over the counter and provide a great insight on how food and your diabetes medications affect your blood sugar levels.” When you monitor your blood sugar, you can identify trends based on the foods you eat and the timing of your medications. “Pay attention to how you feel after eating certain foods. If you notice a pattern of feeling unwell or having unusual blood sugar readings after a particular meal, it’s a good idea to talk to your doctor or a registered dietitian,” says Rosario.

    Consider All Medications and Supplements: “Other medications and supplements can affect blood sugar or interact with diabetes drugs, so it’s important to consider your full medication list when planning meals,” says Zajac. Pharmacists are an important resource to patients when identifying potential food-drug interactions.

    Managing diabetes requires paying close attention to when and what you eat as well as the timing of your medication. You should adjust your diet to allow room for the foods you enjoy while also limiting those that may cause significant interactions with your diabetes medications like those high in added sugars, saturated fat, highly processed carbohydrates, and caffeine.

    Monitoring your blood sugar is the best way to ensure your current plan is working for you. But seeking the care of a registered dietitian or other healthcare provider can be helpful to provide guidance and support, especially if you’re newly diagnosed. “Bottom line, it is important to work with your healthcare professional to be educated on possible side effects of your medication so you can better manage your blood sugar levels and prevent side effects,” says Riker.

    Continue Reading

  • Structural inertia and the struggle to shift coal’s role in China’s power system – Centre for Research on Energy and Clean Air

    The Centre for Research on Energy and Clean Air (CREA) and Global Energy Monitor (GEM) have released their H1 2025 biannual review of China’s coal projects, which finds that coal power additions are continuing to grow.

    Although there were some signs of coal power slowing down in 2024 and 2025 has seen China’s clean energy boom meet a significant amount of power demand growth and lower CO2 emissions, coal power remains strong, with new and revived projects the highest in a decade. 

    In H1 2025,  21 gigawatts (GW) of coal power were commissioned, the highest amount in the first half of the year since 2016, with projections for the full year exceeding 80 GW. This increase in commissions follows on the tail of the 2022-2023 coal power permitting surge that saw two new coal projects permitted per week, on average, totalling more than 100 GW of coal power approved per year. This trend will likely continue into 2026 and 2027, unless policy action is taken.

    Only 25 GW were permitted in H1 2025, yet new and revived projects came to 75 GW in H1 2025, the highest in a decade, and construction starts and restarts reached 46 GW, equivalent to the entire coal power capacity of South Korea. 

    This rush of activity signals possible pressure from the industry to expand coal projects as a last ditch effort before China’s 2030 carbon peaking deadline, right when strategic phase-down should be the priority to meet climate goals and as clean energy is meeting all of new power demand growth.

    In June 2025, coal’s share in power generation dropped to a nine-year low of 51%, and only made up 34% of China’s total installed capacity, while renewables accounted for 60%, pointing to the ongoing trend of coal losing steam while an artificial push attempts to expand rather than phase down its historic role.

    Although China pledged in 2022 that coal should play a flexible, supporting role while renewables are integrated, this policy has yet to be implemented in any meaningful way. Further reform and incentives are needed to transition into scaling down coal power generation and planning a coal exit strategy: in H1 2025, only 1 GW of coal power was retired. 13 GW need to be retired by the end of 2025 to meet the 14th Five-Year Plan goal of retiring 30 GW by the end of 2025. 

    With the Nationally Determined Contributions (NDCs) and 15th Five-Year Plan on the horizon, China has a critical opportunity to set binding targets and initiate policy reform that could confirm China’s role as a global leader in the energy transition. 

    Key findings:

    • Coal power construction and commissioned projects remain high, with no clear signs of slowing. 21 gigawatts (GW) was commissioned in H1 2025, the highest first-half total since 2016. And full-year additions are expected to exceed 80 GW, according to association projections. Construction starts and restarts reached 46GW, equivalent to the entire coal power capacity of South Korea and sustaining the high pace set in 2022.
    • New project approvals remain strong, with signs of pre-carbon peak acceleration. 25 GW was permitted in H1 2025, slightly down from previous years. However, new and revived proposals totalled 75 GW, the highest H1 figure in a decade, reflecting a continued push to advance coal projects before the 2030 carbon peaking deadline.
    • The commissioning boom of 2025 reflects a delayed response to the permitting surge of 2022–2023, when more than 100 GW of coal power was approved each year. Unless policy action is taken, these previously approved projects will continue to drive high levels of commissioning in 2026–2027.
    • Clean energy is expanding at unprecedented speed, reshaping China’s power mix, while coal’s role in generation continues to decline. Wind and solar additions are expected to exceed 500 GW in 2025, which is more than enough to meet total electricity demand growth. Coal’s share in power generation dropped to a historic low of 51% in June 2025. At the same time, renewables account for 60% of total installed capacity, compared to about 34% for coal. Yet coal capacity continues to rise, highlighting a widening disconnect between capacity growth and actual power generation.
    • Coal power is not fulfilling its intended role as a flexible backup for renewables. Current dispatch practices predominantly rely on coal power plants for ramping up power generation when needed, with minimal incentives or explicit requirements to flexibly scale down power generation.
    • China still lacks a coherent coal exit strategy, and power plant retirements are far behind official targets. Only 1 GW of coal power was retired in H1 2025, with just 16 GW retired since 2021. To meet the 14th Five-Year Plan goal of 30 GW by the end of 2025, 13 GW would need to be retired in H2, which appears to be an increasingly unlikely prospect.
    • The upcoming Nationally Determined Contributions (NDCs) and 15th Five-Year Plan offer a crucial opportunity to establish a clear, coordinated roadmap for managing coal power’s decline. While China’s energy policy direction is aligned with long-term climate goals, the absence of binding targets and institutional reform has allowed legacy incentives for coal power to persist. Without stronger national guidance, clean energy progress may be offset by continued coal expansion, delaying energy transition and stalling emission reductions. 

    Policy recommendations

    To align China’s power system with its dual carbon goals and avoid locking in unnecessary coal power capacity, we recommend the following actions:

    • Develop a national roadmap for coal power phase-down. Establish clear national targets and timelines for peaking and reducing coal power capacity, generation and associated emissions, to be incorporated into the upcoming 15th Five-Year Plan. Require provinces to publish their own coal power transition roadmaps, including retirement schedules, to align local actions with national priorities.
    • Tighten permitting standards and cancel non-essential coal power projects. Clearly state that no new conventional coal power plants should be approved in principle during the 15th Five-Year Plan period, with narrowly defined exceptions. Conduct a review of the 2022–2025 permit wave to identify projects that should be cancelled or deferred based on updated system needs.
    • Align provincial actions with national goals. Include coal power reduction progress in performance evaluations of local governments. Promote best practices from early movers and encourage other provinces to follow with peak and phase-down plans.
    • Reform capacity payments to reward flexibility, including for technologies beyond coal plants, like batteries and pumped hydro. Link capacity payments to actual system service delivered, especially ramping down during periods of high renewable generation. Gradually phase out capacity compensation for inflexible or underperforming coal power units.
    • Revise long-term contract structures to reflect system needs. Reduce the share of coal power covered by long-term power purchase agreements. Accelerate the shift from administrative contract guarantees to market-based contracting frameworks.
    • Reform dispatch rules to prioritise renewable integration. Eliminate dispatch practices that give fixed priority to coal output over renewables.
    • Accelerate retirement of inefficient and ageing coal power plants. Create a retirement incentive mechanism, including financial compensation, land reuse support, and workforce transition planning.

    Continue Reading

  • Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

    SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a global Phase 3 clinical trial (MarsLight-11) of IBI363 in immunotherapy(IO)-resistant squamous non-small cell lung cancer (NSCLC). IBI363 is Innovent’s self-discovered novel PD-1/IL-2α-bias bispecific antibody fusion protein. The upcoming study will be the first global Phase 3 trial of IBI363 and represents a significant milestone in advancing a first-in-class, dual-immune activation immunotherapy for this large patient population. Besides, the pivotal trial of IBI363 head-to-head against pembrolizumab (Keytruda®) in the treatment of melanoma is underway in China.

    IBI363 as a Next-generation IO therapy Set for First Global Phase 3 Lung Cancer Trial

    This IND clearance follows recent positive feedback from the U.S. FDA at the End-of-Phase 2 (EOP2) meeting. Major alignments of the Phase 3 program were reached regarding the dose selection, study design, and other critical considerations. Innovent has also received IND approval from China’s National Medical Products Administration (NMPA) for this program. In parallel, Innovent has initiated communications and submissions to other major Health authorities. IBI363 has also received Fast Track Designation (FTD) from the FDA and Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China for this indication.

    The multi-regional, randomized, controlled Phase 3 trial will enroll approximately 600 patients globally including China, U.S., Canada, EU, UK, and Japan, etc. The study will evaluate the efficacy and safety of IBI363 3 mg/kg monotherapy compared with docetaxel in patients with unresectable, locally advanced or metastatic squamous NSCLC who have experienced disease progression following platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. The primary endpoint is overall survival.

    IBI363’s Breakthrough Data Validates its Dual-immune Activation Mechanism, Stepwise Development in Multiple Tumor Types

    At ASCO 2025, Phase 1b/2 results demonstrated meaningful and durable clinical activity in areas of high unmet need, including IO-resistant lung cancer, traditionally “cold tumors” such as acral and mucosal melanoma, and microsatellite stable (MSS) colorectal cancer.

    These promising data position IBI363 as a potential first-in-class dual-immune activation therapy with broad applicability across difficult-to-treat cancers. Innovent is rapidly progressing IBI363 into registrational studies, with a pivotal program in melanoma already ongoing, a global Phase 3 trial in squamous NSCLC expected to start shortly, and a registration strategy in colorectal cancer in planning.

    In parallel, multiple Phase 1b/2 trials are evaluating IBI363 both as monotherapy and in combinations in first-line NSCLC, first-line CRC, and additional tumor types, including platinum-resistant ovarian cancer (PROC), EGFR+ NSCLC, and neoadjuvant therapy for non-squamous NSCLC. This comprehensive development strategy is designed to maximize the value of IBI363 and expand its potential to address multiple large global oncology markets and improve patient outcomes.

    Roy S. Herbst, MD, PhD, Deputy Director and Chief of Medical Oncology and Hematology for Yale Cancer Center and Smilow Cancer Hospital, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale School of Medicine, shared, “Lung cancer remains the most prevalent malignant tumor worldwide, with particularly high incidence and mortality rates globally. Non-small cell lung cancer constitutes the majority of these cases. Although immunotherapy has significantly improved survival outcomes for some patients, those who do not respond to such treatments and lack driver gene mutations have limited therapeutic options, underscoring the urgent need for enhanced clinical interventions.

    Clinical research of the PD-1/IL-2α-biased bispecific molecule IBI363 has revealed encouraging findings.  Preliminary trials have demonstrated that IBI363 not only induces tumor remission in a subset of patients but also achieves disease stability in the majority of patients, indicating durable anti-tumor activity. In comparison to traditional chemotherapy, IBI363 appears to offer potential advantages in both objective response rate (ORR) and progression-free survival (PFS), providing new hope for patients diagnosed with lung cancer.”

    Professor Shun Lu from the Oncology Department of Shanghai Chest Hospital, stated: “As a first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein, IBI363 acts by simultaneously blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is engineered to retain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This dual mechanism targets and activates tumor-specific T cells co-expressing PD-1 and IL-2α, enabling more precise and effective stimulation of this T-cell subpopulation. IBI363 has demonstrated robust antitumor activity across multiple tumor models and has shown remarkable efficacy in IO-resistant, PD-L1 low expression, and cold tumor settings.

    The promising data associated with IBI363 offers a novel treatment avenue for patients with non-small cell lung cancer who have not responded to immunotherapy. As research progresses, this innovative therapy holds the potential to bridge clinical gaps and provide the possibility of long-term survival for a greater number of patients.”

    Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, “Today’s IND clearance marks a significant milestone as we initiate the first global Phase 3 trial of our next-generation IO therapy, IBI363 (PD-1/IL-2α-bias). If successful, this trial could bring a potentially transformative treatment to patients with squamous NSCLC worldwide, who currently have limited options after checkpoint inhibitor therapy. Concurrently, we are exploring IBI363 in a broad global clinical program and look forward to more data and continued development in the future.

    This achievement also signifies a milestone for Innovent’s global innovation strategy, rooted in our mission to ’empower patients worldwide with affordable, high-quality biopharmaceuticals’ and our vision to ‘build a global premier biopharmaceutical leader.’ Having developed a highly competitive pipeline aligned with our globalization strategy, we have prioritized the global R&D of our assets, alongside expanding our international team and footprint to accelerate the development and access of innovative therapies worldwide.

    In addition to IBI363, Innovent is advancing a broader pipeline for global development, including next-generation ADC programs such as bispecific and dual-payload ADCs. We believe our robust pipeline and ongoing R&D efforts will continue to expand our impact in oncology on a global scale.”

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement:

    （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    （2）Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company.

    Forward-Looking Statements

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics, Inc. (“Innovent” or “Company”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

    The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • Study finds the “king of poisons” is building up in global rice fields

    Study finds the “king of poisons” is building up in global rice fields

    Rice feeds billions. It thrives in warm, wet fields and stores energy in a way that fits busy lives and tight budgets. Those same flooded fields can also make arsenic more available to rice plants, and some of that arsenic can end up in the grain.

    A growing body of field evidence points to a new twist: as the planet warms and CO₂ rises, flooded soils lose oxygen more often and for longer stretches. That chemical shift frees arsenic from soil particles, and rice roots take up more of it.

    Climate, rice, and arsenic


    After years of outdoor trials, researchers report that climate conditions expected by mid-century would increase the flow of inorganic arsenic – the harmful form – from soil to plant to grain.

    The work appears in a leading medical journal and was conducted by teams at Columbia University’s Mailman School of Public Health, with collaborators in China and the United States.

    “Our results suggest that this increase in arsenic levels could significantly elevate the incidence of heart disease, diabetes, and other non-cancer health effects,” explained Dr. Lewis Ziska, associate professor of Environmental Health Sciences at the Columbia Mailman School.

    Why arsenic is in rice

    Arsenic occurs naturally in many soils and waters. In paddies that stay flooded, oxygen dwindles. Iron minerals that normally bind arsenic dissolve, and arsenic becomes more mobile.

    Warmer conditions paired with higher CO₂ push that chemistry along, especially in fields that remain waterlogged.

    Under future settings – temperatures more than 2°C (about 3.6°F) above pre-industrial levels plus elevated CO₂ – the balance tilts toward more inorganic arsenic entering the plant.

    That does not make every bowl risky. Local geology, irrigation sources, soil type, and farming practices all shape grain levels. It does mean that the odds can shift in places where paddies stay saturated for long periods.

    Studying rice and arsenic

    The scientists did not rely on short greenhouse trials. They grew 28 rice varieties outdoors for roughly a decade using a Free-Air CO₂ Enrichment (FACE) system.

    This process releases extra CO₂ around crops in the open air so that sunlight, wind, microbes, and soil behave as they do in real life.

    Those long-running field data then fed into models linking plant arsenic levels to typical rice intake and body size across major rice-eating countries in Asia.

    The projections indicate a sizable shift in risk. Lifetime cancer risks, particularly for lung and bladder cancer, increased by 44% relative to ambient conditions. China alone may face 19.3 million excess cancer cases related to arsenic exposure through rice.

    “From a health perspective, the toxicological effects of chronic iAs exposure are well established; and include cancers of the lung, bladder, and skin, as well as ischemic heart disease,” said Dr. Ziska.

    Non-cancer outcomes also matter. The modeling points to increased risks for cardiovascular and metabolic diseases tied to long-term inorganic arsenic exposure in populations with high rice intake.

    Where risks are the highest

    Diet and water sources shape exposure. Regions where rice is a daily staple and paddies are often kept flooded will see the largest impacts under warmer, CO₂-richer conditions.

    “Ingesting rice in regions like southern China and Southeast and South Asia is already a significant source of dietary arsenic and cancer risk,” said Dr. Ziska.

    Within countries, irrigation that draws from arsenic-rich groundwater can raise grain levels. Varieties also differ in how strongly they transport arsenic from roots to grain, which creates room for practical solutions.

    This is bad, what can be done?

    Plant breeding can help: select and develop varieties that limit arsenic uptake even when soils push it toward the roots. Breeders already see large differences among rice lines in how much arsenic reaches the grain.

    Water management is another lever. Continuous flooding increases arsenic mobility, while giving soils time to drain lets oxygen return, which can hold arsenic in less available forms.

    Post-harvest steps matter too. Milling and cooking methods can reduce how much arsenic ends up on the plate.

    No single fix works everywhere. Shifting water regimes, for example, can raise cadmium in some settings, so local testing and tailored management are essential to avoid trading one problem for another.

    Limits and moving parts

    Any mid-century projection carries uncertainty. Policies can bend emissions paths, and farmers adapt as technology and economics shift.

    Diets change with income, urbanization, and migration. The underlying processes are well established. The decade of fieldwork done for this study adds weight because it includes real weather, pests, and microbial communities.

    Rice, arsenic, and human health

    Rice remains a staple food, and the findings from this research don’t claim that every bowl on every table becomes unsafe. Instead, the scientists point to smarter ways of managing risk and a need to act upstream.

    Farmers can adjust irrigation where feasible. Breeders can favor varieties that move less arsenic to the grain. Public health agencies can track arsenic in grains and irrigation sources to guide choices in hotspots.

    “Our study underscores the urgent need for action to reduce arsenic exposure in rice, especially as climate change continues to affect global food security,” said Dr. Ziska.

    Keeping rice safe in a warming world is within reach: breed smarter, water smarter, process smarter—and cut emissions, because the air over our fields follows us to the table.

    The full study was published in the journal The Lancet Planetary Health.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • Ratcheteer DX Has Been Announced For 2026 Release

    Ratcheteer DX Has Been Announced For 2026 Release

    Posted in: Games, Indie Games, Video Games | Tagged: Panic Inc., Ratcheteer DX, Shaun Inman

    Ratcheteer is getting a retro kinf of upgrade, as the original Playdate game becomes Ratcheteer DX for PC and consoles next year

    Article Summary

    • Ratcheteer DX brings the classic Playdate adventure to PC and Nintendo Switch in full color for 2026.

    • Embark on a hero’s journey through 250+ rooms, mastering eight tools and exploring six regions.

    • Enjoy upgraded graphics, CD-quality stereo soundtrack, and support for 10 different languages.

    • Battle six unique bosses, find secret challenges, and unlock retro visual modes for nostalgia.

    In a really fun retro kind of move, solo indie game developer Shaun Inman and publisher Panic Inc. have announced that Ratcheteer DX is coming out next year. The game was originally released for the Playdate as just Ratcheteer when the pocket console first debuted. Now, paying homage to the way many titles upgraded from the Game Boy era to the Nintendo DS, this full-color upgraded experience will bring that game to PC and Nintendo Switch players next year, with tons of upgrades and improvements that go beyond the original turn-crank controls. We have more details here as we now wait for a release date.

    Ratcheteer DX Has Been Announced For 2026 Release
    Credit: Panic Inc.

    Ratcheteer DX

    The surface has been claimed by an Impact Winter, but beneath the ice and earth, mankind hibernates. As a young apprentice mechanic, you wake up in the dark. The Power Plant is offline. The Water Treatment Plant seems to be too. The Cryo Colony is in danger! What begins as a simple trip to fetch your mentor’s wrench sets off a winding journey through the caverns below to a vast Snowcean above to rescue friends, foes, and strangers alike.

    Along the way, you’ll find and master eight unassuming tools, each opening new paths for exploration. Starting with just the Crank Lantern to light your first steps into the dark and the Wrench Sword to swing at what you find lurking in it, you’ll be bounding, drilling, gliding, stomping, and dashing your way across the world of the Ratcheteer by the time you reach the end. Originally released for the black-and-white Playdate, this updated version reimagines the game in full color with a CD-quality stereo soundtrack and support for 10 languages.

    • Explore more than 250 rooms across six regions and six dungeons
    • Master eight unassuming tools and maybe even an alien language
    • Challenge six unique bosses (can you find the secret boss rush time trial?)
    • Play in full Color, Pea Soup green, Playdate gray, or high contrast black-and-white (with optional scanline, grid, and dot overlays)
    • Listen to Matthew Grimm’s 8-bit masterpiece with CD-quality stereo sound
    • Experience an original story in 10 supported languages

    Enjoyed this? Please share on social media!

    Stay up-to-date and support the site by following Bleeding Cool on Google News today!


    Continue Reading

  • Russia’s Top Diplomat Says No Meeting Is Planned Between Putin and Zelensky – The New York Times

    1. Russia’s Top Diplomat Says No Meeting Is Planned Between Putin and Zelensky  The New York Times
    2. Russia is trying to stop meeting on peace and prolong war, Zelensky says  BBC
    3. Russia’s foreign minister says no Putin-Zelenskyy summit planned despite Trump’s peace push  NBC News
    4. Russia rejects Zelensky meeting as diplomatic tension simmers  Dawn
    5. Rome, Geneva, Budapest or … – Which venue for a possible meeting of Presidents Trump, Zelensky and Putin and the possible role of Art. 16 of the Rome Statute?  EJIL: Talk!

    Continue Reading

  • SpaceX postpones Starship test flight over ground system issue – Reuters

    1. SpaceX postpones Starship test flight over ground system issue  Reuters
    2. The most powerful rocket ever built is set for its next test. Here’s why some experts are worried  CNN
    3. What time is SpaceX’s Starship Flight 10 launch today? How to watch it live  Space
    4. SpaceX eyes Starship reusability milestones in rocket’s tenth flight test  The Express Tribune
    5. SpaceX’s Expensive Starship Explosions Are Starting to Add Up  Bloomberg

    Continue Reading

  • Oil Edges Higher Amid Supply Disruption Prospects – The Wall Street Journal

    1. Oil Edges Higher Amid Supply Disruption Prospects  The Wall Street Journal
    2. Oil Moves Higher for a Third Day on Strong Summer Demand  富途牛牛
    3. Oil extends gains amid signs of strong demand  MSN
    4. US Oil Prices Climb On Summer Driving Demand  Finimize
    5. Asian markets remained mixed while oil extends gains into second day  Cryptopolitan

    Continue Reading

  • Australia's Santos extends exclusivity period for $18.7 billion ADNOC-led offer – Reuters

    1. Australia’s Santos extends exclusivity period for $18.7 billion ADNOC-led offer  Reuters
    2. Disturbing history behind company in Santos takeover bid  Australian Broadcasting Corporation
    3. Assessing the ADNOC-Santos Takeover: Regulatory and Geopolitical Risks Reshape Global LNG Investment Strategies  AInvest
    4. Santos suitor opens union talks as gas demands sharpen  The Australian
    5. XRG and Carlyle ‘aligned’ on growth investments to secure Santos’ future  Capital Brief

    Continue Reading